Munich-based smartbax has completed a second closing of its Pre-Series A financing round, bringing the total to €6.3 million after an additional investment from a Frankfurt-based single family office.
The investor syndicate includes Anobis Asset, Bayern Kapital, Boehringer Ingelheim Venture Fund, HTGF and UnternehmerTUM Funding for Innovators.
The funding will support preclinical development and IND filing for smartbax’s lead antibacterial program, which was in-licensed from Aicuris, while also advancing the company’s proprietary pipeline of small-molecule antibiotics.
Founded in 2021, smartbax is developing next-generation antibiotics aimed at multi-drug resistant bacteria. Its pipeline includes a lead program targeting lipopolysaccharide synthesis in Gram-negative bacteria, alongside other small-molecule approaches designed to tackle resistant pathogens through novel mechanisms.
The investor syndicate includes Anobis Asset, Bayern Kapital, Boehringer Ingelheim Venture Fund, HTGF and UnternehmerTUM Funding for Innovators.
The funding will support preclinical development and IND filing for smartbax’s lead antibacterial program, which was in-licensed from Aicuris, while also advancing the company’s proprietary pipeline of small-molecule antibiotics.
Founded in 2021, smartbax is developing next-generation antibiotics aimed at multi-drug resistant bacteria. Its pipeline includes a lead program targeting lipopolysaccharide synthesis in Gram-negative bacteria, alongside other small-molecule approaches designed to tackle resistant pathogens through novel mechanisms.